BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10700572
• 负责人: SUBHRA MOHAPATRA
• 金额: --
• 依托单位: JAMES A. HALEY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-01 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10700572
• 关键词: 3-Dimensional; Academy; Acute; Affect; Alzheimer' s disease related dementia; American; Anti-Inflammatory Agents; Appointment; Area; Artificial Intelligence; Award; Biomedical Engineering; Biopsy; Biotechnology; CCL20 gene; COVID-19; COVID-19 patient; COVID-19 treatment; Cell Therapy; Cell model; Cells; Chronic; Chronic Disease; Clinical Research; Clinical Trials; Collaborations; Colorectal Cancer; Communicable Diseases; Data; Dedications; Dendrimers; Development; Developmental Therapeutics Program; Diagnostic; Disease; Drug Packaging; Drug Targeting; Entrepreneurship; Extramural Activities; Faculty; Florida; Funding; General Population; Graduate Education; Health; Healthcare; Hospitals; Human; Immunocompetent; In Vitro; Incidence; Individual; Industry Collaboration; Inflammation; International; Investigation; Journals; Leadership; Legal patent; Licensing; Literature; Long COVID; Lung diseases; Malignant Neoplasms; Malignant neoplasm of lung; Medical; Medicine; Mentors; Mesenchymal Stem Cells; Modeling; Molecular; Molecular Medicine; Mus; Nerve Regeneration; Neurocognitive; Neurodegenerative Disorders; Oligosaccharides; Oncolytic; Pathogenesis; Population; Property; Publications; Research; Research Activity; Research Personnel; Research Support; Respiratory Syncytial Virus Infections; SARS-CoV-2 antiviral; SARS-CoV-2 infection; Safety; Scientist; Services; Small Interfering RNA; System; Testing; Therapeutic; Therapeutic Research; Time; Training; Translational Research; Traumatic Brain Injury; United States Department of Veterans Affairs; United States National Institutes of Health; Universities; Veterans; Viral; Viral Respiratory Tract Infection; Virus Diseases; Virus Replication; X-Ray Computed Tomography; career; chest computed tomography; clinical diagnosis; clinical diagnostics; college; combinatorial; coronavirus disease; cytokine release syndrome; efficacy evaluation; human disease; improved; in vivo; indexing; inhibitor; innovation; malignant breast neoplasm; mouse model; nano; nanoformulation; nanomedicine; nanoparticle; nanoscale; nanotherapeutic; nervous system disorder; novel; novel diagnostics; novel virus; pandemic disease; particle; prognostic; programs; prophylactic; research clinical testing; senior faculty; stem cell therapy; therapeutically effective

This proposal seeks to renew Research Career Scientist Award held by Dr. Subhra Mohapatra, at the James A. Haley VA Hospital in Tampa, Florida since 2018. She is also a tenured- full professor (part-time) at the VA-affiliated academic center- the University of South Florida. She is the recipient of several international/national awards and recognitions including as a Fellow of the National Academy of Inventors and a Fellow of the American Institute for Medical and Biological Engineering. Dr. Mohapatra has been a research investigator at the VA Hospital (Medicine) since 2007 and has been continuously funded with the Merit Review Award focused on cancer, traumatic brain injury (TBI), and COVID since 2016. She has been studying the basic molecular and translational mechanisms underlying the inflammation in diverse acute/chronic diseases including COVID-19, cancers, and TBI, all of which afflict VA population and contribute significantly to the overall health of the Veterans. The main premise of her research program has been to understand the mechanisms involved in the disease pathogenesis toward developing novel diagnostic/prognostic and therapeutic approaches to treat them. Current and ongoing research activities to be supported by this RCS Award focus on three areas. The first program centers on the characterization of novel virus-neutralizing nanoparticles that may serve as prophylactic and/or treatment for COVID-19 patients. In this proposal, these particles will be investigated for their potential and validated in relevant human cellular and mouse models. She is collaborating with other VA investigators in developing an additional project to develop novel siRNA-based prophylactic and therapeutic approaches targeting viral replication and cytokine storm that follows acute SARS- CoV-2 infection. The second research program focuses on the investigation of a novel combinatorial therapeutic approach in a mouse model of moderate TBI that includes an intranasal dendrimer-based nano-formulated siRNA treatment against a recently discovered target, CCL20 to reduce inflammation, and a parallel treatment to promote neuroregeneration by therapy with mesenchymal stem cells. In the third research program Dr. Mohapatra’s lab aims to investigate and test a novel targeted oncolytic viro-cell therapy for lung cancer using the mesenchymal stem cells infected by a respiratory syncytial virus infection, which is harmless for immunocompetent individuals. This project uses a 3D multicell tumoroid in vitro and biopsy-derived cultures ex vivo, which her lab has pioneered. Further, this project uses in vivo mouse models of lung cancer to evaluate the safety and efficacy of oncolytic viro-cell therapy. The project to date has attracted industry collaboration, which might lead to clinical trials. Overall, these highly innovative approaches taken together are expected to lead to high-impact clinical diagnostics and therapies for diverse diseases of Veterans and other Americans in need. Veterans have been proportionately affected by the pandemic and are increasingly affected by the incidence of lung cancers and TBI compared to the general population. With ~100 publications, 20 patents, an h- index of 36 and an i-index of 85, Dr. Subhra Mohapatra is recognized nationally and internationally for her contributions to the fields of research on cancer, neurodegenerative disease, and viral infections. She has received substantial extramural research support including awards from the NIH, ONR, Department of Veterans Affairs, and Florida Department of Health. It is anticipated that the development of these effective therapeutics will greatly improve the quality of Veteran’s healthcare.

该建议旨在续签Subhra博士颁布的研究职业科学家奖。 Mohapatra，自2018年以来在佛罗里达州坦帕的詹姆斯·Haley VA医院举行 VA附属学术中心的完整教授（兼职） - 南佛罗里达大学。她 是获得几项国际/国家奖项和认可的获得者，包括 美国国家发明家学院和美国医学与生物学研究所的会员 工程。 Mohapatra博士一直是VA医院（医学）的研究人员 2007年，并一直凭借有关癌症的优点评论奖的持续资助 自2016年以来，脑损伤（TBI）和Covid。 潜水员急性/慢性疾病的炎症基础的翻译机制包括 COVID-19，CANCERS和TBI，所有这些都会影响VA人口，并对 退伍军人的整体健康。她的研究计划的主要前提是 了解疾病发病机理涉及的机制 诊断/预后和治疗方法来治疗它们。当前和正在进行的研究 该RCS奖将重点关注三个领域的活动。第一个程序以 可以用作预防性和/或的新型病毒中和纳米颗粒的表征 COVID-19患者的治疗。在此提案中，将研究这些粒子的潜力 并在相关的人类细胞和小鼠模型中进行了验证。她正在与其他VA合作 研究人员开发了一个额外的项目，以开发新的基于siRNA的预防性和 靶向病毒复制和细胞因子风暴的治疗方法，伴随着急性SARS- COV-2感染。第二项研究计划的重点是对小说的调查 中等TBI的小鼠模型中的组合治疗方法，包括鼻内 针对最近发现的靶标CCL20 TO的基于树枝状聚合物的纳米成型siRNA处理 减少感染和平行治疗，以促进通过治疗 间充质干细胞。在第三项研究计划中，Mohapatra博士的实验室旨在调查 并使用间充质茎测试新的针对肺癌肺癌的肺癌治疗肺癌 受呼吸道合胞病毒感染感染的细胞，对免疫能力无害 个人。该项目在体外和活检衍生的培养物中使用3D多细胞肿瘤类体内， 她的实验室开创性的。此外，该项目使用肺癌的体内小鼠模型 评估溶瘤病毒细胞疗法的安全性和效率。迄今为止的项目吸引了 行业合作，可能会导致临床试验。总体而言，这些高度创新的 预计共同的方法将导致高影响力的临床诊断和疗法 对于退伍军人和其他有需要的美国人的潜水疾病。退伍军人曾经 受到大流行的比例影响，越来越受肺部的影响 与普通人群相比，癌症和TBI。约有100份出版物，20份专利，H- Subhra Mohapatra博士在全国认可，为36的I-Index和85岁的I索引。 在国际上，她对癌症研究领域的贡献，神经退行性疾病， 和病毒感染。她获得了大量的校外研究支持，包括奖项 来自NIH，ONR，退伍军人事务部和佛罗里达卫生部。这是 预计这些有效的治疗剂的发展将大大提高 老兵的医疗保健。

项目成果

Hyperoxia-induced cardiotoxicity and ventricular remodeling in type-II diabetes mice.

高氧诱导的 II 型糖尿病小鼠心脏毒性和心室重塑。

• DOI: 10.1007/s00380-017-1100-6
• 发表时间: 2018
• 期刊: Heart and vessels
• 影响因子: 1.5
• 作者: Rodgers,JenniferLeigh;Samal,Eva;Mohapatra,Subhra;Panguluri,SivaKumar
• 通讯作者: Panguluri,SivaKumar

Molecular mechanism-driven new biomarkers and therapies for atopic dermatitis.

分子机制驱动的特应性皮炎新生物标志物和疗法。

• DOI: 10.1016/j.jaci.2020.04.039
• 发表时间: 2020
• 期刊: The Journal of allergy and clinical immunology
• 作者: Mohapatra,ShyamS;Mohapatra,Subhra;McGill,AndrewR;Green,Ryan
• 通讯作者: Green,Ryan

Elevated potassium outward currents in hyperoxia treated atrial cardiomyocytes.

高氧处理的心房心肌细胞中钾外向电流升高。

• DOI: 10.1002/jcp.26263
• 发表时间: 2018
• 期刊: Journal of cellular physiology
• 影响因子: 5.6
• 作者: Vysotskaya,Zhanna;Chidipi,Bojjibabu;Rodgers,JenniferL;Tang,Xiaolan;Samal,Eva;Kolliputi,Narasaiah;Mohapatra,Subhra;Bennett,EricS;Panguluri,SivaK
• 通讯作者: Panguluri,SivaK

Emerging Nano-Formulations and Nanomedicines Applications for Ocular Drug Delivery.

• DOI: 10.3390/nano11010173
• 发表时间: 2021-01-12
• 期刊: Nanomaterials (Basel, Switzerland)
• 作者: Khiev D;Mohamed ZA;Vichare R;Paulson R;Bhatia S;Mohapatra S;Lobo GP;Valapala M;Kerur N;Passaglia CL;Mohapatra SS;Biswal MR
• 通讯作者: Biswal MR

The design and characterization of a gravitational microfluidic platform for drug sensitivity assay in colorectal perfused Tumoroid cultures.

• DOI: 10.1016/j.nano.2020.102294
• 发表时间: 2020-08
• 期刊: Nanomedicine : nanotechnology, biology, and medicine
• 作者: Tao Wang;R. Green;M. Howell;T. Martinez;Rinku Dutta;S. Mohapatra;S. Mohapatra